Moxonidine

Overview

Moxonidine is a new-generation centrally acting antihypertensive drug approved for the treatment of mild to moderate essential hypertension. It is suggested to be effective in cases where other agents such as thiazides, beta-blockers, ACE inhibitors, and calcium channel blockers are not appropriate or irresponsive. As well, moxonidine has been shown to present blood pressure-independent beneficial effects on insulin resistance syndrome.

Indication

For the treatment of mild to moderate essential or primary hypertension . Effective as most first-line antihypertensives when used as monotherapy .

Associated Conditions

Hypertension

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Sympathetic Mechanisms in Obesity-Crossover Design	2022/04/06	NCT05312892	Phase 1	Recruiting	Vanderbilt University Medical Center
Moxonidine Effects on Neuropeptide Y	2021/12/07	NCT05147753	Phase 4	Completed	Aristotle University Of Thessaloniki
Role of Sympathetic Activation in Ischemia Reperfusion Injury	2020/07/21	NCT04479813	Phase 4	Completed	Royal Perth Hospital
Sympathoinhibition as a Preferred Second Line Treatment of Obesity Related Hypertension	2020/07/17	NCT04474899	Phase 4	Recruiting	Royal Perth Hospital
Sympathetic Mechanisms in the Cardiovascular and Metabolic Alterations of Obesity	2020/04/01	NCT04329806	Phase 1	Terminated	Italo Biaggioni
Autonomic Determinants of POTS - Pilot 2	2019/10/28	NCT04140721	Early Phase 1	Active, not recruiting	Vanderbilt University Medical Center
Autonomic Determinants of POTS - Pilot1	2019/08/08	NCT04050410	Early Phase 1	Active, not recruiting	Vanderbilt University Medical Center
Comparative Effects of Moxonidine on Bone Metabolism, Vascular and Cellular Aging in Hypertensive Postmenopausal Women	2015/02/04	NCT02355821	Not Applicable	Completed	National Research Center for Preventive Medicine
Moxonidine for Prevention of Post-ablation AFib Recurrences	2013/02/15	NCT01791699	Phase 4	Completed	Spyridon Deftereos
Alleviating the Metabolic Side Effects of Antipsychotic Medications	2012/03/30	NCT01567124	Phase 4	Withdrawn	Baker Heart and Diabetes Institute

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
MOXOTENS moxonidine 400 microgram tablet blister pack	300129	Arrotex Pharmaceuticals Pty Ltd	Medicine	A	7/2/2019
MOXONIDINE LAPL moxonidine 200 microgram film-coated tablet blister pack	291315	Lupin Australia Pty Limited	Medicine	A	7/9/2018
MOXONIDINE GX moxonidine 200 microgram tablet blister pack	287646	Viatris Pty Ltd	Medicine	A	1/25/2018
MOXONIDINE VIATRIS moxonidine 400 microgram tablet blister pack	287645	Viatris Pty Ltd	Medicine	A	1/25/2018
MOXONIDINE SCP moxonidine 400 microgram film-coated tablet blister pack	285635	Southern Cross Pharma Pty Ltd	Medicine	A	1/16/2018
MOXONIDINE GPPL moxonidine 400 microgram tablet blister pack	300128	Arrotex Pharmaceuticals Pty Ltd	Medicine	A	7/2/2019
MOXONIDINE GENPAR moxonidine 400 microgram tablet blister pack	300133	Arrotex Pharmaceuticals Pty Ltd	Medicine	A	7/2/2019
MOXONIDINE GH moxonidine 400 microgram film-coated tablet blister pack	291317	Lupin Australia Pty Limited	Medicine	A	7/9/2018
MOXONIDINE SCP moxonidine 200 microgram film-coated tablet blister pack	285627	Southern Cross Pharma Pty Ltd	Medicine	A	1/16/2018
MOXONIDINE-WGR moxonidine 200 microgram tablet blister pack	300130	GM Pharma International Pty Ltd	Medicine	A	7/2/2019

Health Canada Drug Approvals

Approved Product	Company	DIN	Dosage Form	Strength	Market Date
No Health Canada approvals found for this drug.

CIMA AEMPS Drug Approvals

Approved Product	Company	Registration Number	Pharmaceutical Form	Prescription Type	Status
MOXON 0,2 mg COMPRIMIDOS RECUBIERTOS CON PELICULA	Viatris Healthcare Limited	61156	COMPRIMIDO RECUBIERTO	Medicamento Sujeto A Prescripción Médica	Commercialized
MOXON 0,3 mg COMPRIMIDOS RECUBIERTOS CON PELICULA	Viatris Healthcare Limited	61157	COMPRIMIDO RECUBIERTO	Medicamento Sujeto A Prescripción Médica	Commercialized
MOXON 0,4 mg COMPRIMIDOS RECUBIERTOS CON PELICULA	Viatris Healthcare Limited	61158	COMPRIMIDO RECUBIERTO	Medicamento Sujeto A Prescripción Médica	Commercialized

Philippines FDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product	Company	Registration Number	Dosage Form	Strength	Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name	MA Holder	MA Number	Pharmaceutical Form	Active Ingredient	Authorization Date
No UK EMC drug information found for this drug.

AI-Powered Research

Premium Access